Sepsis Awareness Month: Highlighting the Findings from BLINGIII Trial

The B-Lactam Antibiotic Infusion Trial, led by Dr. Jeffrey Lipman, could significantly change sepsis management. The study, involving 7,200 patients, compared continuous and intermittent β-lactam antibiotic infusions. While it showed no significant reduction in 90-day mortality, Lipman highlighted a positive trend with a 1.9% reduction.
Supporting this, a systematic review indicated that continuous infusions could improve mortality rates. Lipman anticipates a global shift toward continuous infusions for severe sepsis. He also called for more precise antibiotic use and shorter treatment courses to combat antibiotic resistance.
Read more: www.contagionl...